u/NiceGuy0606

The author argues Intellia cleared major hurdles with FDA acceptance of the lonvo-z BLA under Priority Review, a March 10, 2027 PDUFA date, and no planned AdCom, which is framed as strong confidence in the Phase 3 package. A $400M non-dilutive OrbiMed credit facility extends runway past 2028, and nex-z enrollment in MAGNITUDE-2 is on track for H2 2026. The author sees lonvo-z potentially becoming the first approved in vivo CRISPR medicine and a one-time HAE treatment. Main risks include clinical/regulatory setbacks and the need to resolve prior safety signals via HLA-genotyping.